Rapid HBV DNA decrease is the most important prognostic factor for first line treatment with Adefovir dipivoxil in HBeAg positive and negative patients with chronic hepatitis B

Aims: In the present study the nucleoside analogue adefovir dipivoxil (ADV) was used as first-line monotherapy for treatment of CHB in treatment-naive patients. The aim was to estimate the effect of viral factors such as HBV genotype, viral load and viral kinetics on treatment response after 48 and 96 weeks. Methods: Data of sixty-six patients (60% males, 65% HBeAg negative) were analyzed. All patients received 10mg adefovir QD. Quantitative HBV DNA and ALT levels were determined at 4, 12, 24, 48, 72 and 96 weeks. HBV genotyping was performed at baseline whereas serological testing was performed at baseline, 24,…